Critical Path for Parkinson's Consortium: Advancing Drug Development Tools and Regulatory Science for PD therapeutic trials

被引：0

作者：

Romero, K. ^{[1
]}

Akalu, M. ^{[1
]}

Alexander, R. ^{[2
]}

Bloem, B. R. ^{[4
]}

Boroojerdi, B. ^{[3
]}

Burn, D. ^{[5
]}

Cedarbaum, J. ^{[6
]}

Conrado, D. ^{[1
]}

Dexter, D. T. ^{[7
]}

Dorsey, E. R. ^{[8
,12
]}

Facheris, M. ^{[9
]}

Fischer, T. ^{[10
]}

Frasier, M. ^{[11
]}

Gallagher, J. ^{[7
]}

Gordon, M. Forrest ^{[12
]}

Grosset, D. ^{[13
]}

Hill, D. ^{[12
]}

Ho, C. ^{[14
]}

Hu, M. T. ^{[15
]}

Kieburtz, K. ^{[8
,12
]}

Lassen, A. B. ^{[16
]}

Lawson, R. ^{[5
]}

Macha, S. ^{[17
]}

Marek, K. ^{[18
]}

Taylor, K. ^{[19
]}

Russell, D. ^{[18
]}

Seibyl, J. ^{[18
]}

Stafford, B. ^{[1
]}

Stebbins, G. ^{[20
]}

Venuto, C. ^{[8
,12
]}

Williams-Gray, C. ^{[21
]}

Yarnall, A. ^{[5
]}

Stephenson, D. ^{[1
]}

机构：

[1] Crit Path Inst, Tucson, AZ USA

[2] Takeda, Tokyo, Japan

[3] UCB Pharma, Brussels, Belgium

[4] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[5] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England

[6] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA

[7] Parkinsons UK, London, England

[8] Univ Rochester, Rochester, NY 14627 USA

[9] AbbVie Inc, N Chicago, IL USA

[10] Sanofi, Paris, France

[11] Michael J Fox Fdn, New York, NY USA

[12] Advisor CPP, Toronto, ON, Canada

[13] Univ Glasgow, Glasgow, Lanark, Scotland

[14] Denali Therapeut, San Francisco, CA USA

[15] Univ Oxford, Oxford, England

[16] Lundbeck, Copenhagen, Denmark

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Inst Neurodegenerat Disorders, New Haven, CT USA

[19] Roche, Basel, Switzerland

[20] Rush Univ, Advisor CPP, Chicago, IL 60612 USA

[21] Univ Cambridge, Cambridge, England

来源：

MOVEMENT DISORDERS | 2019年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S17 / S17

页数：1

共 46 条

[41] THE PD-HI: DEVELOPMENT AND VALIDATION OF A NOVEL, DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURE FOR PARKINSON'S DISEASE CLINICAL TRIALS
Seabury, J.
Weinstein, J.
Varma, A.
Rosero, S.
Engebrecht, C.
Irwin, C.
Shupe, C.
Arky, A.
Heatwole, J.
Zizzi, C.
Dilek, N.
Purks, J.
Adams, J.
Dorsey, E. R.
Heatwole, C.
PARKINSONISM & RELATED DISORDERS, 2024, 122
[42] Evaluation of regional changes in striatal DAT binding in a progressing Parkinson's disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials
Seibyl, J. P.
Jennings, D.
Marek, K.
MOVEMENT DISORDERS, 2016, 31 : S265 - S266
[43] Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease - Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications
Moreadith, Randall W.
Viegas, Tacey X.
Bentley, Michael D.
Harris, J. Milton
Fang, Zhihao
Yoon, Kunsang
Dizman, Bekir
Weimer, Rebecca
Rae, Brendan P.
Li, Xiuling
Rader, Christoph
Standaert, David
Olanow, Warren
EUROPEAN POLYMER JOURNAL, 2017, 88 : 524 - 552
[44] Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson's disease (PD): Are We Doing It Right? A Systematic Review and Meta-Analysis
Reis Rodrigues, F.
Pasqualotto, E.
Ribeiro, G.
Couto, J. M.
Bayram, E.
Ushe, M.
Di Luca, D.
MOVEMENT DISORDERS, 2024, 39 : S387 - S387
[45] Regulatory science under the Generic Drug User Fee Act of 2012 (GDUFA), including FDA's consideration of complex drug substances and innovative analytical method development
Jiang, Xiaohui
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[46] Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson's disease patients with motor fluctuations (TOZ-PD)
Kerwood, F.
Kenney, C.
Kieburtz, K.
Olanow, W.
Resburg, C.
Krishnaswami, J.
Bandak, S.
MOVEMENT DISORDERS, 2016, 31 : S696 - S697

← 1 2 3 4 5 →